Table 2.

Comparison of CPRD and DIN patient cohorts by exposure to BPLM in the year prior to cancer diagnosis

	All patients				Other BPLMs but no β-blockers				β-Blockers plus other BPLMs				β-Blockers only (β-blockers but no other BPLMs)
	CPRD		DIN		CPRD		DIN		CPRD		DIN		CPRD		DIN
	N	Per cent	N	Per cent	N	Per cent	N	Per cent	N	Per cent	N	Per cent	N	Per cent	N	Per cent
All patients	11 302	100	3462	100	7272	64.3	2056	59.4	2832	25.10	864	24.4	1198	10.6	542	15.7
Deaths	5754	50.1	1441	41.6	3748	51.6	846	41.2	1459	51.5	350	40.5	547	45.7	245	45.2
Alive at 1-year follow-up	8763	77.5	2576	74.4	5607	77.1	1541	75.0	2194	77.5	630	72.9	962	80.3	405	74.7
On non-selective β-blocker	685	6.06	239	7.5	NA	NA	NA	NA	359	12.7	71	8.2	326	27.2	167	30.8
Cancer sites
Breast	2943	26.0	984	28.4	1746	24.0	554	26.9	794	28.0	240	27.8	403	33.6	194	35.8
Colon	1799	15.9	619	17.9	1104	15.2	354	17.2	476	16.8	162	18.7	219	18.3	103	18.9
Lung	1326	11.7	436	12.6	913	12.6	277	13.5	307	10.9	105	12.1	106	8.8	54	9.9
Oesophagus	434	3.8	159	4.6	257	3.5	95	4.6	116	4.1	44	5.1	61	5.1	20	3.7
Ovarian	203	1.8	148	4.3	124	1.7	76	3.7	45	1.6	43	5.0	34	2.8	29	5.4
Pancreas	376	3.3	140	4.0	222	3.1	83	4.0	111	4.0	34	3.9	43	3.6	23	4.2
Prostate	3748	33.2	759	21.9	2604	35.8	500	24.3	856	30.2	182	21.0	288	24.0	77	14.1
Renal	141	1.2	124	3.6	81	1.1	69	3.4	48	1.7	33	3.8	12	1.0	22	4.0
Stomach	332	2.9c	93	2.7	221	3.0	52	2.5	79	2.8	21	2.4	32	2.7	20	3.7

BPLMs, blood pressure lowering medicines; CPRD, Clinical Practice Research Datalink; DIN, Doctors’ Independent Network; NA, not applicable.